| Product Code: ETC13249874 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Dry Age Macular Degeneration Market was valued at USD 9.7 Billion in 2024 and is expected to reach USD 14.3 Billion by 2031, growing at a compound annual growth rate of 9.48% during the forecast period (2025-2031).
The Global Dry Age Macular Degeneration (AMD) Market is experiencing steady growth due to the rising prevalence of AMD, particularly in the aging population. The market is driven by the increasing awareness about the disease, advancements in diagnostic techniques, and the development of novel treatment options such as anti-VEGF therapies and gene therapies. Key players in the market are focusing on research and development activities to introduce innovative products and expand their market presence. Additionally, collaborations and partnerships between pharmaceutical companies and research institutions are contributing to the growth of the market. As the demand for effective treatments for dry AMD continues to rise, the market is expected to witness further expansion in the coming years, with North America and Europe being the major regions driving market growth.
The Global Dry Age Macular Degeneration Market is experiencing growth driven by increasing prevalence of the disease due to aging populations, lifestyle changes, and rising awareness of eye health. Emerging treatment options such as anti-VEGF therapies and gene therapies are offering new hope for patients, leading to a shift towards earlier diagnosis and intervention. Technological advancements in diagnostic tools and imaging techniques are also improving the accuracy of diagnosis and disease monitoring. Moreover, collaborations between pharmaceutical companies and research institutions are fueling innovation in drug development and personalized medicine approaches. Opportunities in the market include expanding into emerging markets, developing novel therapies targeting specific disease pathways, and leveraging artificial intelligence for early detection and treatment optimization. Overall, the Global Dry Age Macular Degeneration Market presents promising prospects for growth and advancement in the coming years.
The Global Dry Age Macular Degeneration Market faces several challenges, including the lack of effective treatment options, limited understanding of the disease`s underlying mechanisms, and the high cost of existing therapies. Additionally, the aging population worldwide is increasing the prevalence of the condition, putting further strain on healthcare systems and resources. Furthermore, the competitive landscape in the market is intense, with pharmaceutical companies racing to develop innovative drugs to address the unmet medical needs of patients with dry age-related macular degeneration. Regulatory hurdles, such as lengthy approval processes for new treatments, also pose a significant challenge for market players. Overall, navigating these obstacles requires strategic partnerships, robust research and development efforts, and a deep understanding of the evolving market dynamics.
The Global Dry Age Macular Degeneration (AMD) market is primarily driven by the increasing prevalence of AMD among the aging population worldwide. The rising awareness about early diagnosis and treatment options, advancements in diagnostic technologies, and the development of novel therapies are also key drivers fueling market growth. Additionally, the growing demand for effective AMD treatment options, the availability of government initiatives to support AMD research, and the expanding research and development activities in the field of ophthalmology are contributing factors to the market expansion. Moreover, the increasing healthcare expenditure, improving healthcare infrastructure, and the rising focus on preventive healthcare measures are expected to further drive the growth of the Global Dry AMD market in the coming years.
Government policies related to the Global Dry Age Macular Degeneration Market typically focus on regulating the approval and pricing of treatments, promoting research and development initiatives, and ensuring patient access to innovative therapies. Regulatory bodies such as the FDA in the United States and the EMA in Europe play a crucial role in evaluating the safety and efficacy of new treatments for dry age-related macular degeneration (AMD) before they can be commercialized. Governments also often provide funding and incentives to support research efforts aimed at developing new therapies and improving patient outcomes. Additionally, policies may address issues related to healthcare reimbursement and insurance coverage to ensure that patients have access to necessary treatments without facing financial burdens. Overall, government policies in this market aim to facilitate innovation, ensure patient safety, and improve healthcare accessibility for individuals affected by dry AMD.
The global dry age-related macular degeneration market is expected to witness steady growth in the coming years, driven by factors such as an increasing geriatric population, rising prevalence of age-related macular degeneration, and advancements in diagnostic and treatment options. Technological innovations in imaging techniques and drug development are likely to enhance the management of the disease, leading to improved patient outcomes. Additionally, the growing awareness about preventive measures and early detection among healthcare professionals and patients is anticipated to contribute to market growth. However, factors such as high treatment costs, limited access to healthcare services in some regions, and stringent regulatory requirements may present challenges to market expansion. Overall, the market is projected to show promising growth opportunities, with a focus on personalized and targeted therapies for dry age-related macular degeneration.
In the Global Dry Age Macular Degeneration market, North America is a major region due to the high prevalence of the disease, advanced healthcare infrastructure, and increasing research and development activities in the region. Europe follows closely behind with a significant market share, driven by a growing aging population and government initiatives to improve access to treatment. Asia Pacific is expected to witness rapid growth in the market due to the increasing awareness about eye health, improving healthcare facilities, and rising disposable income levels. In the Middle East and Africa region, the market is primarily driven by the rising geriatric population and improving healthcare infrastructure. Latin America is also showing promising growth opportunities due to the increasing prevalence of age-related macular degeneration and the focus on expanding healthcare services in the region.
Global Dry Age Macular Degeneration Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Dry Age Macular Degeneration Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Dry Age Macular Degeneration Market Revenues & Volume, 2021 & 2031F |
3.3 Global Dry Age Macular Degeneration Market - Industry Life Cycle |
3.4 Global Dry Age Macular Degeneration Market - Porter's Five Forces |
3.5 Global Dry Age Macular Degeneration Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Dry Age Macular Degeneration Market Revenues & Volume Share, By Stages, 2021 & 2031F |
3.7 Global Dry Age Macular Degeneration Market Revenues & Volume Share, By Age Group, 2021 & 2031F |
3.8 Global Dry Age Macular Degeneration Market Revenues & Volume Share, By Diagnosis and Treatment, 2021 & 2031F |
3.9 Global Dry Age Macular Degeneration Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Global Dry Age Macular Degeneration Market Revenues & Volume Share, By End Users, 2021 & 2031F |
4 Global Dry Age Macular Degeneration Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Dry Age Macular Degeneration Market Trends |
6 Global Dry Age Macular Degeneration Market, 2021 - 2031 |
6.1 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Stages, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Early Age-Related Macular Degeneration, 2021 - 2031 |
6.1.3 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Intermediate Age-Related Macular Degeneration, 2021 - 2031 |
6.1.4 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Late Age-Related Macular Degeneration, 2021 - 2031 |
6.2 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Age Group, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Above 75 Years, 2021 - 2031 |
6.2.3 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Above 60 Years, 2021 - 2031 |
6.2.4 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Above 40 Years, 2021 - 2031 |
6.3 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnosis and Treatment, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Treatment, 2021 - 2031 |
6.3.3 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnosis, 2021 - 2031 |
6.4 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Oral, 2021 - 2031 |
6.4.3 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Injectables, 2021 - 2031 |
6.5 Global Dry Age Macular Degeneration Market, Revenues & Volume, By End Users, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Hospitals & Clinics, 2021 - 2031 |
6.5.3 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnostic Centers, 2021 - 2031 |
6.5.4 Global Dry Age Macular Degeneration Market, Revenues & Volume, By Academic & Research Institutes, 2021 - 2031 |
7 North America Dry Age Macular Degeneration Market, Overview & Analysis |
7.1 North America Dry Age Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
7.2 North America Dry Age Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Dry Age Macular Degeneration Market, Revenues & Volume, By Stages, 2021 - 2031 |
7.4 North America Dry Age Macular Degeneration Market, Revenues & Volume, By Age Group, 2021 - 2031 |
7.5 North America Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnosis and Treatment, 2021 - 2031 |
7.6 North America Dry Age Macular Degeneration Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.7 North America Dry Age Macular Degeneration Market, Revenues & Volume, By End Users, 2021 - 2031 |
8 Latin America (LATAM) Dry Age Macular Degeneration Market, Overview & Analysis |
8.1 Latin America (LATAM) Dry Age Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Dry Age Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Dry Age Macular Degeneration Market, Revenues & Volume, By Stages, 2021 - 2031 |
8.4 Latin America (LATAM) Dry Age Macular Degeneration Market, Revenues & Volume, By Age Group, 2021 - 2031 |
8.5 Latin America (LATAM) Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnosis and Treatment, 2021 - 2031 |
8.6 Latin America (LATAM) Dry Age Macular Degeneration Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
8.7 Latin America (LATAM) Dry Age Macular Degeneration Market, Revenues & Volume, By End Users, 2021 - 2031 |
9 Asia Dry Age Macular Degeneration Market, Overview & Analysis |
9.1 Asia Dry Age Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Dry Age Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Dry Age Macular Degeneration Market, Revenues & Volume, By Stages, 2021 - 2031 |
9.4 Asia Dry Age Macular Degeneration Market, Revenues & Volume, By Age Group, 2021 - 2031 |
9.5 Asia Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnosis and Treatment, 2021 - 2031 |
9.6 Asia Dry Age Macular Degeneration Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
9.7 Asia Dry Age Macular Degeneration Market, Revenues & Volume, By End Users, 2021 - 2031 |
10 Africa Dry Age Macular Degeneration Market, Overview & Analysis |
10.1 Africa Dry Age Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Dry Age Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Dry Age Macular Degeneration Market, Revenues & Volume, By Stages, 2021 - 2031 |
10.4 Africa Dry Age Macular Degeneration Market, Revenues & Volume, By Age Group, 2021 - 2031 |
10.5 Africa Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnosis and Treatment, 2021 - 2031 |
10.6 Africa Dry Age Macular Degeneration Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
10.7 Africa Dry Age Macular Degeneration Market, Revenues & Volume, By End Users, 2021 - 2031 |
11 Europe Dry Age Macular Degeneration Market, Overview & Analysis |
11.1 Europe Dry Age Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Dry Age Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Dry Age Macular Degeneration Market, Revenues & Volume, By Stages, 2021 - 2031 |
11.4 Europe Dry Age Macular Degeneration Market, Revenues & Volume, By Age Group, 2021 - 2031 |
11.5 Europe Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnosis and Treatment, 2021 - 2031 |
11.6 Europe Dry Age Macular Degeneration Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
11.7 Europe Dry Age Macular Degeneration Market, Revenues & Volume, By End Users, 2021 - 2031 |
12 Middle East Dry Age Macular Degeneration Market, Overview & Analysis |
12.1 Middle East Dry Age Macular Degeneration Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Dry Age Macular Degeneration Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Dry Age Macular Degeneration Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Dry Age Macular Degeneration Market, Revenues & Volume, By Stages, 2021 - 2031 |
12.4 Middle East Dry Age Macular Degeneration Market, Revenues & Volume, By Age Group, 2021 - 2031 |
12.5 Middle East Dry Age Macular Degeneration Market, Revenues & Volume, By Diagnosis and Treatment, 2021 - 2031 |
12.6 Middle East Dry Age Macular Degeneration Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
12.7 Middle East Dry Age Macular Degeneration Market, Revenues & Volume, By End Users, 2021 - 2031 |
13 Global Dry Age Macular Degeneration Market Key Performance Indicators |
14 Global Dry Age Macular Degeneration Market - Export/Import By Countries Assessment |
15 Global Dry Age Macular Degeneration Market - Opportunity Assessment |
15.1 Global Dry Age Macular Degeneration Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Dry Age Macular Degeneration Market Opportunity Assessment, By Stages, 2021 & 2031F |
15.3 Global Dry Age Macular Degeneration Market Opportunity Assessment, By Age Group, 2021 & 2031F |
15.4 Global Dry Age Macular Degeneration Market Opportunity Assessment, By Diagnosis and Treatment, 2021 & 2031F |
15.5 Global Dry Age Macular Degeneration Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
15.6 Global Dry Age Macular Degeneration Market Opportunity Assessment, By End Users, 2021 & 2031F |
16 Global Dry Age Macular Degeneration Market - Competitive Landscape |
16.1 Global Dry Age Macular Degeneration Market Revenue Share, By Companies, 2024 |
16.2 Global Dry Age Macular Degeneration Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here